{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:07:00Z","timestamp":1770282420115,"version":"3.49.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Uteroplacental insufficiency associated disorders, such as preeclampsia, fetal growth restriction and obstetrical antiphospholipid syndrome, share pathophysiology and risk factors with cardiovascular diseases treated with statins.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To evaluate pregnancy outcomes among women with uteroplacental insufficiency disorders who were treated with statins.<\/jats:p><jats:p><jats:bold>Search Strategy:<\/jats:bold> Electronic databases were searched from inception to January 2022<\/jats:p><jats:p><jats:bold>Selection Criteria:<\/jats:bold> Cohort studies and randomized controlled trials.<\/jats:p><jats:p><jats:bold>Data collection and analysis:<\/jats:bold> Pooled odds ratios were calculated using a random-effects model; meta-regression was utilized when applicable.<\/jats:p><jats:p><jats:bold>Main Results:<\/jats:bold> The analysis included ten studies describing 1,391 women with uteroplacental insufficiency disorders: 703 treated with pravastatin and 688 not treated with statins. Women treated with pravastatin demonstrated significant prolongation of pregnancy (mean difference 0.44 weeks, 95%CI:0.01\u20130.87, <jats:italic>p<\/jats:italic> = 0.04, I<jats:sup>2<\/jats:sup> = 96%) and less neonatal intensive care unit admissions (OR = 0.42, 95%CI: 0.23\u20130.75, <jats:italic>p<\/jats:italic> = 0.004, I<jats:sup>2<\/jats:sup> = 25%). In subgroup analysis, prolongation of pregnancy from study entry to delivery was statistically significant in cohort studies (mean difference 8.93 weeks, 95%CI:4.22\u201313.95, <jats:italic>p<\/jats:italic> = 0.00) but not in randomized control studies. Trends were observed toward a decrease in preeclampsia diagnoses (OR = 0.54, 95%CI:0.27\u20131.09, <jats:italic>p<\/jats:italic> = 0.09, I = 44%), perinatal death (OR = 0.32, 95%CI:0.09\u20131.13, <jats:italic>p<\/jats:italic> = 0.08, I<jats:sup>2<\/jats:sup> = 54%) and an increase in birth weight (mean difference = 102 g, 95%CI: -14\u2013212, <jats:italic>p<\/jats:italic> = 0.08, I<jats:sup>2<\/jats:sup> = 96%). A meta-regression analysis demonstrated an association between earlier gestational age at initiation of treatment and a lower risk of preeclampsia development (R<jats:sup>2<\/jats:sup> = 1).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Pravastatin treatment prolonged pregnancy duration and improved associated obstetrical outcomes in pregnancies complicated with uteroplacental insufficiency disorders in cohort studies.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link> identifier CRD42020165804 17\/2\/2020.<\/jats:p>","DOI":"10.3389\/fphar.2022.1021548","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T07:59:52Z","timestamp":1667980792000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Pravastatin and placental insufficiency associated disorders: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ayala","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reut","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natali","family":"Ternovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruria","family":"Hirsh Raccah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.thromres.2011.02.006","article-title":"The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis","volume":"128","author":"Abou-Nassar","year":"2011","journal-title":"Thromb. Res."},{"key":"B2","first-page":"168","article-title":"Clinical management guidelines for obstetrician \u2013 gynecologists","volume":"133","year":"2020","journal-title":"Obstetrics Gynecol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/1471-0528.16013","article-title":"Pravastatin for early-onset pre-eclampsia: A randomised, blinded, placebo-controlled trial","volume":"127","author":"Ahmed","year":"2020","journal-title":"BJOG"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1055\/a-1673-5603","article-title":"INOVASIA study: A randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1\/PlGF levels","volume":"47","author":"Akbar","year":"2021","journal-title":"Am. J. Perinatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: Cohort study","volume":"350","author":"Bateman","year":"2015","journal-title":"BMJ (Online)."},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosissup.2018.04.401","volume-title":"Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies","author":"Botha","year":"2018"},{"key":"B8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.115.05445","article-title":"Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia","volume":"66","author":"Brownfoot","year":"2015","journal-title":"Hypertension"},{"key":"B9","doi-asserted-by":"publisher","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials","volume":"339","author":"Brugts","year":"2009","journal-title":"BMJ (Online)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MOL.0b013e3283453e41","article-title":"Mechanisms for the anti-inflammatory effects of statins","volume":"22","author":"Bu","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"B11","article-title":"Role of fibrated and HMG-CoA reductase inhibitors in gallstone formation","volume":"46","author":"Caroli-Bosc","year":"2001","journal-title":"Disgestive Dis. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.siny.2004.03.006","article-title":"Developmental biology of the placenta and the origins of placental insufficiency","volume":"9","author":"Chaddha","year":"2004","journal-title":"Semin. Fetal Neonatal Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/pds.1995","article-title":"Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens","volume":"19","author":"Colvin","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: A pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/j.ajog.2021.11.142","article-title":"Long-term child follow-up of the pravastatin for prevention of preeclampsia pilot trials","volume":"226","author":"Costantine","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"666.e1","DOI":"10.1016\/j.ajog.2021.05.018","article-title":"A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia","volume":"225","author":"Costantine","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1753944708094227","article-title":"Preeclampsia and future cardiovascular risk: Formal risk factor or failed stress test?","volume":"2","author":"Craici","year":"2008","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.106.660134","article-title":"Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1","volume":"115","author":"Cudmore","year":"2007","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"01735300","DOI":"10.1371\/journal.pone.0173530","article-title":"Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies","volume":"12","author":"Daud","year":"2017","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.enfcli.2019.07.147","article-title":"The effect of pravastatin on endothelin-1 levels and pregnancy outcomes in women who have a high risk for preeclampsia: A randomized control trial","volume":"30","author":"Deviana","year":"2020","journal-title":"Enferm. Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.121.053963","article-title":"Pravastatin versus placebo in pregnancies at high risk of term preeclampsia","volume":"144","author":"Dobert","year":"2021","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajmg.a.30386","article-title":"Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins","author":"Edison","year":"2004","journal-title":"Am. J. Med. Genet. A"},{"key":"B25","first-page":"461","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"22","author":"Ga Wells","year":"1932","journal-title":"Round Table"},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.sa.0000151206.53344.39","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"49","author":"Gaiser","year":"2005","journal-title":"Surv. Anesthesiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1515\/jpm-2017-0109","article-title":"Is pravastatin a milestone in the prevention and treatment of preeclampsia?","volume":"46","author":"Gajzlerska-Majewska","year":"2018","journal-title":"J. Perinat. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.siny.2015.12.007","article-title":"Global burden of prematurity","volume":"21","author":"Harrison","year":"2016","journal-title":"Semin. Fetal Neonatal Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.7326\/M18-0808","article-title":"Statins and multiple noncardiovascular outcomes: Umbrella review of meta-Analyses of observational studies and randomized controlled trials","volume":"169","author":"He","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Online)"},{"key":"B31","first-page":"1","article-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019","journal-title":"Cochrane Handb. Syst. Rev. Interventions"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ajog.2016.03.001","article-title":"Placental origins of adverse pregnancy outcomes: Potential molecular targets: An executive workshop summary of the eunice kennedy shriver national institute of child health and human development","volume":"215","author":"Ilekis","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B34","doi-asserted-by":"publisher","first-page":"106824","DOI":"10.1016\/j.vph.2020.106824","article-title":"Pravastatin plus L-arginine prevents adverse pregnancy outcomes in women with uteroplacental vascular dysfunction","volume":"137","author":"Jurisic","year":"2021","journal-title":"Vasc. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.reprotox.2020.04.058","article-title":"The outcomes of statin exposure in pregnancy","volume":"97","author":"Kadioglu","year":"2020","journal-title":"Reprod. Toxicol."},{"key":"B36","volume-title":"Pravastatin is useful for prevention of recurrent severe placenta-mediated complications \u2013 a pilot s _ Enhanced Reader","author":"Kupferminc","year":"2021"},{"key":"B37","doi-asserted-by":"publisher","first-page":"31725","DOI":"10.1074\/jbc.272.50.31725","article-title":"Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase","volume":"272","author":"Laufs","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijcard.2018.07.002","article-title":"Statin exposure during first trimester of pregnancy is associated with fetal ventricular septal defect","volume":"269","author":"Lee","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1172\/JCI86957","article-title":"Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy","volume":"126","author":"Lefkou","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"114217","DOI":"10.1016\/j.bcp.2020.114217","article-title":"Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism","volume":"182","author":"Lefkou","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/pds.4176","article-title":"Statins during pregnancy: A cohort study using the general practice research database to investigate pregnancy loss","volume":"26","author":"McGrogan","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1055\/s-0040-1713651","article-title":"Evaluating the effect of pravastatin in early-onset fetal growth restriction: A nonrandomized and historically controlled pilot study","volume":"1","author":"Mendoza","year":"2020","journal-title":"Am. J. Perinatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1161\/CIR.0b013e31820faaf8","article-title":"Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: A guideline from the American Heart association","volume":"123","author":"Mosca","year":"2011","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1365-2125.2007.02905.x","article-title":"Risk of congenital anomalies in pregnant users of statin drugs","volume":"64","author":"Ofori","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B47","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/bdra.20181","article-title":"Pregnancy outcomes after maternal exposure to simvastatin and lovastatin","volume":"73","author":"Pollack","year":"2005","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jacc.2005.05.086","article-title":"The potential relevance of the multiple lipid-independent (Pleiotropic) effects of statins in the management of acute coronary syndromes","volume":"46","author":"Ray","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"101768","DOI":"10.1016\/j.redox.2020.101768","article-title":"MZe786, a hydrogen sulfide-releasing aspirin prevents preeclampsia in heme oxygenase-1 haplodeficient pregnancy under high soluble flt-1 environment","volume":"38","author":"Rezai","year":"20212020","journal-title":"Redox Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0140-6736(00)03577-7","article-title":"Pathogenesis and genetics of pre-eclampsia","volume":"357","author":"Roberts","year":"2001","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijcard.2014.09.013","article-title":"Cardiac medication during pregnancy, data from the ROPAC","volume":"177","author":"Ruys Titia","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/1933719113492207","article-title":"Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia","volume":"21","author":"Saad","year":"2014","journal-title":"Reprod. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"101768","DOI":"10.1016\/j.redox.2020.101768","article-title":"MZe786, a hydrogen sulfide-releasing aspirin prevents preeclampsia in heme oxygenase-1 haplodeficient pregnancy under high soluble flt-1 environment","volume":"38","author":"Saif","year":"2021","journal-title":"Redox Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"106490","DOI":"10.1016\/j.cct.2021.106490","article-title":"A randomized phase 3 trial evaluating antithrombin gamma treatment in Japanese patients with early-onset severe preeclampsia (KOUNO-TORI study): Study protocol","volume":"107","author":"Saito","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology\/American Heart association task force on practice guidelines","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"B56","volume-title":"Meta-analysis of observational studies","author":"Stroup","year":"2021"},{"key":"B57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.reprotox.2008.06.009","article-title":"Prenatal exposure to HMG-CoA reductase inhibitors: Effects on fetal and neonatal outcomes","volume":"26","author":"Taguchi","year":"2008","journal-title":"Reprod. Toxicol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIRCULATIONAHA.110.990929","article-title":"Pregnancy outcomes in familial hypercholesterolemia: A registry-based study","volume":"124","author":"Toleikyte","year":"2011","journal-title":"Circulation"},{"key":"B59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5551\/jat1973.18.2_165","article-title":"HMG-CoA reductase inhibitors","volume":"18","author":"Tsujita","year":"1990","journal-title":"J. Jpn. Atheroscler. Soc."},{"key":"B60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2021.05.006","article-title":"Fetal toxicity associated with statins: A systematic review and meta-analysis","volume":"327","author":"Vahedian-Azimi","year":"2021","journal-title":"Atherosclerosis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.112.145334","article-title":"Statins as antithrombotic drugs","volume":"127","author":"Violi","year":"2013","journal-title":"Circulation"},{"key":"B62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2007.11.004","article-title":"Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results","volume":"14","author":"Wang","year":"2008","journal-title":"Trends Mol. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/1471-0528.12066","article-title":"Pregnancy outcome following maternal exposure to statins: A multicentre prospective study","volume":"120","author":"Winterfeld","year":"2013","journal-title":"BJOG"},{"key":"B64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1161\/01.ATV.0000063385.12476.A7","article-title":"Endothelium-dependent effects of statins","volume":"23","author":"Wolfrum","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajog.2019.11.1247","article-title":"The competing risk approach for prediction of preeclampsia","volume":"223","author":"Wright","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1021548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T08:00:01Z","timestamp":1667980801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1021548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":65,"alternative-id":["10.3389\/fphar.2022.1021548"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1021548","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"1021548"}}